Abstract 5-(2-Chloroethyl)-2ʹ-deoxyuridine (CEDU) was developed as an antiviral drug. It has been studied in a number of in vitro and in vivo genotoxicity assays and is considered an unusual nucleoside analogue owing to its potent mutagenic potential, with little to no measurable clastogenic activity. Given this atypical profile, CEDU represented an interesting compound for evaluating the in vivo Pig-a gene mutation assay, a test that is undergoing extensive validation for regulatory safety applications. The current report describes two studies with 7-week-old male Wistar Han rats, one that exposed animals to several dose levels of CEDU for 5 consecutive days, the other for 28 consecutive days. Blood samples were collected at several time points and analysed for Pig-a mutant cell frequencies via flow cytometry. These Pig-a analyses were accompanied by micronucleated reticulocyte (MN-RET) measurements performed with blood samples collected 1 day after cessation of treatment. Both studies showed robust CEDU dose-related increases in Pig-a mutant reticulocytes and mutant erythrocytes. Conversely, neither experiment showed evidence of a CEDU-related MN-RET-inducing effect. These rat haematopoietic cell results were in good agreement with those of earlier mouse studies where in vivo mutagenesis was observed, without clastogenicity/aneuploidy. Taken together, these data add further support to the concept that the Pig-a assay represents an important complement to the widely used in vivo micronucleus assay, as it expands the range of important DNA lesions that can be detected in short-term as well as protracted exposure study designs.
Introduction
When evaluating the genotoxicity of drug candidates, both in vitro and in vivo end points must be considered according to various regulatory guidelines (1) . The in vivo Pig-a assay, now undergoing an extensive validation, will be used for assessing the end point of gene mutation (2) (3) (4) (5) . Following systematic validation efforts, this assay has the potential to be used for regulatory safety work (6) .
The several versions of the rodent blood-based Pig-a assay described to date are all based on the fact that a single inactivating mutation in the X-linked chromosome endogenous Pig-a gene causes a disruption to glycosylphosphatidylinositol (GPI)-anchor synthesis. In the case of an inactivating mutation, GPI-anchored proteins, e.g. CD59, are not expressed on the cell surface of erythrocytes or other haematopoietic cells, and therefore this phenotype serves as a reliable reporter of gene mutation (7) (8) (9) .
Many compounds have been tested using the rodent bloodbased assay, and it is appreciated that potent mutagens can be reliably detected, as well as genotoxicants that are considered strong clastogens with subtler mutagenic activities (10, 11) . To gain further insight into the sensitivity of the assay, compounds with different mechanisms of genotoxic action should be tested. As there is currently limited information about how the Pig-a assay responds to nucleoside analogues (12, 13) , this represents a data gap that should be addressed for validation purposes.
We considered CEDU (5-(2-chloroethyl)-2ʹ-deoxyuridine) to be a particularly interesting nucleoside analogue for testing. It is potent inhibitor of herpes simplex type 1 (HSV-1) proliferation via inhibition of HSV-1 DNA polymerase and cellular DNA polymerase ɑ (14) . Once CEDU becomes incorporated into the DNA, it causes a shift in the nucleoside pool (14) . CEDU has been evaluated in a number of genotoxicity assays. The in vitro tests showed negative results for CEDU mutagenicity and clastogenicity. Whereas a mouse bone marrow micronucleus assay was negative, positive results for a mouse spot test and a transgenic in vivo mutation study (MutaMouse) were indicative of mutagenic potential (15) . On the basis of these results, CEDU is considered an unusual nucleoside analogue, owing to the demonstration of clear mutagenic potential, with little to no measurable clastogenic activity (15) .
In this study, two rat studies were conducted to assess the genotoxicity of CEDU. Short-term (5-day) and long-term (28-day) exposure periods were used for these experiments, and both studies included Pig-a gene mutation as well as micronucleated reticulocyte (MN-RET) assays. The work was anticipated to provide additional insights into the ability of these individual assays to detect genomic damage caused by this nucleoside analogue, as well the combination of the two assays, as they are often represented as being complementary (10, 16, 17) .
Materials and Methods
Reagents and other supplies CEDU (CAS no. 90301-59-0) was synthesised by Novartis (Basel, Switzerland). Lympholyte ® -Mammal cell separation reagent was purchased from Cedarlane (Burlington, NC). Anti-PE MicroBeads, LS columns and a QuadroMACS™ separator were from Miltenyi Biotec (Bergisch Gladbach, Germany). CountBright™ Absolute Count Beads and fetal bovine serum were purchased from Invitrogen (Carlsbad, CA). Anticoagulant solution, buffered salt solution, nucleic acid dye solution (contains SYTO ® 13), anti-CD59-PE and anti-CD61-PE were from Rat Blood In Vivo MutaFlow ® Kits (Litron Laboratories, Rochester, NY). Reagents used for flow cytometric micronucleus scoring (anticoagulant solution, buffered salt solution, stock propidium iodide solution, anti-CD71-FITC and anti-CD61-PE solutions, stock RNase solution and malaria biostandards) were from In Vivo Rat MicroFlow ® Kits (Litron Laboratories).
Animals, treatments, blood harvests
Experiments were conducted in compliance with all applicable Swiss and Novartis regulations that cover laboratory rodent studies. Male Wistar Han rats were obtained from Charles River Laboratories, Germany. Rats were allowed to acclimate at least 5 days, and their age at the start of treatment was 7 weeks. The animals were kept under standard animal room conditions: 12-h light and 12-h dark cycle, 21-25ºC, relative humidity 20-50%, with water and a certified PROVIMI-KLIBA pelleted standard diet from Provimi Kliba AG, Kaiseraugst, available ad libitum. CEDU was prepared in phosphatebuffered saline each day before treatment and was administered via oral gavage in a volume of 10 mL/kg body weight. Six animals were randomly assigned to each of four treatment groups, and dose groups were 0, 500, 1000 and 2000 mg/kg/day for the 5-day study, and 0, 250, 500 and 1000 mg/kg/day for the 28-day study. The doses selection was based on the data published by Suter et al. (15) .
Blood collection occurred 1 day before the start of treatment and again several times following initiation of CEDU exposure. For the 5-day study, blood was collected on Days -1, 6, 14, 28 and 56. For the 28-day study, blood was collected on Days -1, 15, 29 and 40. Blood collection occurred on isoflurane-anaesthetised rats via puncture of the sublingual vein. For the micronucleus assay, 100 µL blood was transferred to tubes containing 350 µL of kit-supplied anticoagulant solution, and in the case of the Pig-a assay, 160 µL blood was added to tubes containing 200 µL anticoagulant solution. For the micronucleus assay, cells were fixed in ultracold methanol and stored at −80°C until analysis occurred, as described later. For Pig-a analyses, blood was maintained at 4°C until analysis occurred, as described later (within the same day of collection).
Micronucleated reticulocytes: sample preparation, data acquisition
Peripheral blood MN-RET frequencies were determined for the 5-and 28-day studies, and this was accomplished using Day 6 and Day 29 specimens, respectively. To prepare samples for flow cytometric analysis, blood was washed out of methanol fixative and incubated with antibodies and other reagents as specified in the In Vivo Mouse MicroFlow Kit manual. This methodology has been described in detail elsewhere (18) . Kit-supplied malaria-infected erythrocytes served as biological standards and guided instrument settings on each day of analysis (19) . The frequency of immature erythrocytes (reticulocytes, RET) and micronucleated immature erythrocytes (micronucleated reticulocytes, MN-RET) were determined upon the acquisition of 20 000 CD71-positive RETs per blood sample. An LSR II flow cytometer (Becton & Dickinson, USA) running FACSDiva software, version 8.1, was used for these analyses.
Pig-a mutation: sample preparation, data acquisition
Pig-a mutant phenotype cell frequencies were determined on blood samples collected before and after initiation of CEDU treatment. Methods for processing rat blood for Pig-a measurements have been described (4, 16) . As with previous reports, the frequencies of RNA-positive RETs, mutant phenotype reticulocytes (RET CD59− ) and mutant phenotype erythrocytes (RBC CD59− ) were determined for each sample. An Instrument Calibration Standard was generated on each day data acquisition occurred. These samples contained a high prevalence of mutant-mimic cells and provided a means to define the location of GPI anchor-deficient erythrocytes (20) . The LSR II flow cytometer running FACSDiva software, version 8.1, was used for the Pig-a analyses.
Calculations, statistical analyses
The incidence of MN-RET and RET are expressed as frequency percent. The formulas used to calculate RET CD59− and RBC CD59− frequencies based on pre-and post-immunomagnetic column data are described in Dertinger et al. (16) and the Rat Blood MutaFlow Kit instruction manual (www.litronlabs.com).
To evaluate the effect that CEDU treatment may have had on %MN-RET, %RET, and RBC CD59− and RET CD59− frequencies relative to concurrent vehicle control rats, we performed Dunnett's multiple comparison t-tests using JMP software's one-way ANOVA platform (v12.0.1; SAS Institute Inc., Cary, NC). With the exception of the %RET end point, each test was performed at the 5% level using a one-tailed test to identify significant increases relative to vehicle control. In the case of %RET, the tests were two-tailed in order to determine whether a significant treatment-related increase or decrease occurred.
Prior to performing the parametric tests described above, Levene's tests were used to verify the equality of variances in the samples (P > 0.05; JMP's ANOVA platform). The following transformations were applied to fulfil this requirement: %MN-RET, RBC CD59− and RET CD59− were log10 transformed. Whenever a zero RET CD59− reading occurred, a 0.1 offset was added to every RET CD59− frequency observed on that day prior to log transformation.
Results

Day study
No outward signs of toxicity were evident for rats treated for 5 days with CEDU, including changes to body weight (data not shown).
Regarding Pig-a assay results, short-term CEDU exposure did not affect %RET frequencies at any time point studied (Figure 1) . Rather, a reduction in %RET was observed with increasing rat age, with 7-week-old animals exhibiting approximately 8% RET and fractionally less than 3% by 15 weeks of age (study termination).
Unlike %RET, RET CD59− frequencies were found to increase upon CEDU exposure. Whereas pretreatment frequencies were uniformly low, by Day 14 each of the CEDU-exposed groups showed statistically significant elevated mean frequencies (Figure 2 ). Whereas the effect was pronounced and maintained across the Day 14, 28 and 56 time points, within group RET CD59− variation appeared to be somewhat greater in CEDU-treated rats at the final sampling time.
In support of increasing RET CD59− frequencies noted earlier, RBC CD59− frequencies were also found to increase in response to CEDU ( Figure 3) . As with RET CD59− , every CEDU-exposed group exhibited a statistically significant increase in RBC CD59− at each time point studied following initiation of treatment. As a lagging indicator of mutation relative to the quickly turning over RET cohort, it is not surprising that the RBC CD59− effect was not maximal until Day 56.
A peripheral blood-based micronucleus test was performed concurrently with the 5-day Pig-a study. As shown by Figure 4 (upper left panel), the high-dose group showed a modest, statistically significant reduction to CD71-positive %RET, evidence that CEDU did reach the bone marrow compartment. Even so, and despite the relatively potent mutation effects that were observed at the Pig-a locus, no appreciable induction of MN-RET was observed (Figure 4 , upper right panel).
No outward signs of toxicity were evident for rats treated for 28 days with CEDU, including changes to body weight (data not shown).
CEDU exposure for 28 days up to the limit dose of 1000 mg/ kg/day did not affect %RET frequencies at any time point studied ( Figure 5 ). As with the 5-day study, the only difference in %RET was across time points, with reduced prevalence of immature erythrocytes with increasing age.
As with the 5 days study, RET CD59− frequencies were found to markedly increase with protracted CEDU exposure ( Figure 6 ). As early as Day 14, each of the CEDU-exposed groups showed statistically significant elevated mean frequencies. The RET CD59− increase was dose-related and appeared to be maximal or nearmaximal by the Day 28 and 40 time points. Whereas the dose levels used in this experiment overlapped with those used in the short-term study (on a per day basis), the total exposure was greater in this experimental design, and this likely explains the higher induced frequencies that were observed. RBC CD59− frequencies were also found to increase in response to CEDU (Figure 7) . Each CEDU-exposed group exhibited a statistically significant increase in RBC CD59− , at each time point subsequent to Day -1. Whereas the dose-related increases were evident at the Day 15 and 29 time points, the RBC CD59− -inducing effect was maximised at Day 40.
As with the short-term study, micronucleus induction was evaluated concurrently with the Pig-a mutation assay. As shown by Figure 4 (lower left and lower right panels), neither %RET nor %MN-RET was significantly affected by CEDU treatment, thereby highlighting a lack of appreciable clastogenic/aneugenic activity, even at the limit dose of 1000 mg/kg/day.
Discussion
CEDU was selected as an interesting nucleoside analogue that would provide more information about the sensitivity of the Pig-a assay, and it furthermore speaks to the premise that it is an especially useful end point when studied in combination with the in vivo micronucleus test. Among Pig-a positives, several have been negative in the in vivo micronucleus or comet assays conducted with the same animals. For example, aristolochic acids have been shown to induce Pig-a mutant cells in a rat model, even though the peripheral blood micronucleus and liver comet assays were negative or equivocal at best (17) . In addition, 4-nitroquinoline-1-oxide is clearly positive for micronucleus and comet assays when conducted using a high-dose, short-term treatment study design, but negative at dose levels that are tolerated for 28 days of treatment (21, 22) . The converse is also true. There are examples of negative Pig-a results in the same rodents that showed elevated frequencies of blood micronuclei. Examples include two nucleoside analogues, 5-fluorouracil (12) and azidothymidine (13) , and the ribonucleotide reductase inhibitor hydroxyurea (16) .
The results presented herein are in agreement with the work of Suter et al., who reported remarkable mutagenic activity for CEDU, with little to no clastogenic potential (15) . However, in the case of the current experiments, the combined Pig-a and MN-RET studies provided this information in a more efficient and 3R's friendly manner, without the need for a dedicated mouse spot test, a bone marrow micronucleus test and a transgenic mouse assay.
In conclusion, results presented herein provide useful information regarding the performance characteristics of the Pig-a assay. First, as noted by others, the assay is compatible with short-term as well as more protracted exposure designs, so long as attention is given to the manifestation time required to develop a GPIanchor-deficient phenotype in peripheral blood reticulocytes and erythrocytes (5, 16) . Second, as the remarkable induction of mutant phenotype blood cells reported herein attest, the Pig-a assay is sensitive to certain nucleoside analogues. Finally, the Pig-a mutation assay, coupled with measurements of cytogenetic damage via the micronucleus end point, represents complementary tests that provide a better picture of chemicals' genotoxic potential relative to either assay alone.
